In Vitro Cytotoxicity and Pharmacokinetic Study for Bosutinib Solid Lipid Nanoparticles

Area of Science:

• Pharmaceutical Sciences
• Drug Delivery Systems
• Nanotechnology

Background:

• Bosutinib (BST), a Biopharmaceutics Classification System Class II drug, exhibits very low solubility and high permeability.
• Poor aqueous solubility and dissolution of BST result in limited oral bioavailability, hindering its therapeutic efficacy.
• Extensive first-pass metabolism contributes to low absolute bioavailability (14-34%) of BST.

Purpose of the Study:

• To investigate the potential of lipid-based drug delivery systems, specifically solid lipid nanoparticles (SLNs), to enhance oral bioavailability of Bosutinib (BST).
• To overcome hepatic first-pass metabolism and improve the therapeutic outcome of BST through optimized SLN formulation.

Main Methods:

• Solid lipid nanoparticles (SLNs) with a size range of 50-1000 nm were prepared using physiological lipids.
• Bosutinib (BST) was loaded into SLNs to leverage intestinal lymphatic transport for improved absorption.
• An optimal BST-SLN formulation was evaluated for its bioavailability in rats compared to BST suspension (SUS).

Main Results:

• In vitro cytotoxicity studies indicated higher percent inhibition for SLN compared to BST suspension (SUS).
• Pharmacokinetic studies in male Wistar rats demonstrated a significant increase in BST bioavailability.
• The oral bioavailability of Bosutinib was enhanced by 2.28-fold when formulated as SLNs compared to BST suspension.

Conclusions:

• Solid lipid nanoparticles (SLNs) are effective lipid-based carrier systems for Bosutinib (BST).
• SLN formulation significantly improves the oral bioavailability of Bosutinib, addressing its poor solubility limitations.
• This approach holds promise for enhancing the therapeutic efficacy of Bosutinib.